According to Adar Poonawalla, CEO of the Serum Institute of India (SII), India may resume the export of COVID-19 vaccines before the end of the year.
Export restrictions on COVID-19 vaccines are expected to be eased in one or two months, according to Poonawalla. According to him, SII, which manufactures Covishield (the Oxford-AstraZeneca vaccine), is also “substantially” increasing its capacity.
“The export restrictions were put in place temporarily to protect our country. We expect it to subside in the next month or two. Because, based on the number of vaccinations we’ve provided and those delivered by others in India, we’re approaching a point where we’ll have more than adequate vaccine supply, especially if we scale up, even more, this year”, According to Poonawalla, he told the publication.
“As a result, we expect exports to diminish during the following two months gradually. But you should also check with the government; in the end, it is their decision, and we will follow their lead “, he added.
According to Poonawalla, India is nearing a point where there is enough stock to continue the vaccine campaign.
During the second wave of COVID-19 in India, the country temporarily banned vaccine exports. India had already exported dosages to several countries.
Since then, the production and supply of dosages have increased. According to the health ministry’s statement on September 17, India has administered over 77 crores (770 million) doses.
According to the American news website Axios, the US has asked India to resume vaccine exports.
SII committed to providing 550 million Covishield doses to COVAX, a global project that ensures equitable distribution of COVID-19 vaccination doses to persons in low- and middle-income countries by 2020.